Services - Products

Welcome to INDEVION Biotechnologies

COMPANY

Dear Visitor, Welcome to our website. Contact us at info@indevion.eu, or Phone +36 30 371 6208.

INDEVION Biotech is a broad scientific knowledge and know-how-based research and development company. The company has a potent strategic partner and integrated infrastructure network built to guarantee cutting-edge technology and customised solutions for a wide range of biomolecular and cellular challanges in biopharmaceutical development. The company has a proven track record of development and execution of various technology intensive projects leading to novel intellectual property. Fields of experties is summarised below in an incomplete and growing list.

>PORTFOLIO<

DRUG DISCOVERY

PROTEIN ENGINEERING

RECOMBINANT PROTEINS

MANUFACTURING

ANIMAL MODELS

>R&D ACTIVITIES<

Cancer Therapeutics Development

Cell and Genome engineering project development and execution

Stable cell line development projects – reporters, effectos, producers

Recombinant protein and DNA technology and production

Antibody development and production

Cytokine development and production

Bionanotech-based platform technology for drug development

Glycosylation diagnostics and quality control

>PROJECT EXAMPLES< Go to Competencies

Please, contact us for further information: info@indevion.eu

Protein and Cell Technologies

We offer advanced protein expression and engineering technologies, design, de novo design, mutagenesis, directed evolution services, and cell line development and engineering solutions to meet the need of customers from research labs  to the biopharmaceutical industry.

>PROTEIN EXPRESSION<

PROTEIN DESIGN – MUTAGENESIS

LIBRARY GENERATION – DIRECTED MOLECULAR EVOLUTION

>CELL LINE DEVELOPMENT<

Genome engineering – Speialty and custom cell lines

Cutting-edge technology consultation, project development and execution.

>GENERAL SERVICE PORTFOLIO<

CONTRACT RESEARCH AND DEVELOPMENT

JOINT INTELLECTUAL PROPERTY DEVELOPMENT

BIOSIMILARS DEVELOPMENT

CUSTOM PROTEIN PRODUCTION – PURIFICATION – CHARACTERISATION

PROTEIN DESIGN AND ENGINEERING

BIOTECH CONSULTATION

>STRATEGIC PARTNERS<

ERACAN CORPORATION:

PROXENCELL - PROTEIN EXPRESSION AND CELL ENGINEERING LABS:

UD-GENOMED – MEDICAL GENOMIC TECHNOLOGIES LTD

 

See References

 

GENERAL TECHNOLOGIES

Recombinant protein and DNA

Monoclonal antibody

Cell culture, transient transfection and stable cell lines

Protein production, purification, biochemical and biological characterisation

>INFRASTRUCTURE<

Strategic integrated infrastructure for

PROTEIN EXPRESSION & ENGINEERING

CELL CULTURE & ENGINEERING

GENOMICS, PROTEOMICS, STEM CELL

CELLULAR AND MOLECULAR RESEARCH AND DEVELOPMENT

 

 

 

General facilities and services

1. Recombinant proteins

- production (bacterial, yeast, insect, mammalian)

- purification (LC, FPLC, HPLC – affinity, gel filtration, ion-exchange chromatography)

- characterisation (CD, MS, Fluorescence, CE, SDS/PAGE, Western, ELISA, BiaCore )

2. Gene-to-Protein service (from custom DNA sequence to engineered proteins)

3. Protein Engineering (mutagenesis, structure-based design, directed molecular evolution)

4. Cell culture and cell line engineering laboratories

5. Phage display selection technology (peptides, proteins, mimotope, antibody, IVE)

6. Large-scale fermentation (2-100 L) and downstream processing.

7. Antibody development and production (from target DNA sequence to monoclonal antibodies)

8. Cytokine development and production (recombinant and labelled cytokines

experience

PRODUCTS

Our product pipeline is going public soon.

Recombinant proteins

Antibodies

Cytokines

… growing.

INDEVION BIOTECH – YOUR PARTNER in proprietary technology and product development

Company info

INDEVION Biotechnology R&D Ltd
Balassi Bálint u. 6. 1/10.
Debrecen H-4032 Hungary
Tel: +36 30 371 6208
E-mail: info@indevion.eu

01.09.2017. INDEVION stars designing and directing a protein engineering and in vitro evolution based biological drug development project contracted by the University of Debrecen as a 'biotech know-how' company partner.

05.02.2017. INDEVION initiates an anti-cancer drug development pre-clinical project using animal tumor model based efficacy studies.

01.04.2016. ERACAN Corporation was established as a partner therapeutic development company by the assistence of INDEVION consulting. "EraCan is a closed share corporation developing and marketing therapeutic and preventive technologies to effectively handle a broad range of cancers. Peptide based and ionic technologies are in the portfolio, which, together with accessory components and protocols help us "ERADICATE CANCER".

04.28.2015: INDEVION Biotech initiates biopharmaceutical producer industrial CHO cell line development projects for Big Pharma in alliance with UD-GenoMed.

01.28.2015: INDEVION Biotech is starting to assemble and coordinating the establishment of a Swiss-based strategic biotechnology investment and management corporation (NEXTACURE SA).
"NEXtACURE CORPORATION IS UNDER FORMATION AS A SWISS-BASED INVESTMENT COMPANY WITH A FOCUS ON THERAPIES, DIAGNOSTICS, BIOTECH R&D, MEDTECH AND PERSONALISED HEALTHCARE SOLUTIONS WITH AN EMPHASIS ON KNOWLEDGE SYSTEMS INTEGRATION - WE DEVELOP ACTUAL AND NATURAL CURES FOR DISTRESSING DISEASES"

01.08.2014: INDEVION Biotech initiates work on project and business plans to establish a a new startup company targeting novel therapeutic antibody technology and diagnostics development jointly with UD-GenoMed and the Center for Clinical Genomics and Personalised Medicine at the University of Debrecen.

10.01.2014: INDEVION Biotech signs contract for new ADC (antibody drug conjugate) technology development project with UD-GenoMed-Covalab Consortium.

04.11.2013: New publication by INDEVION staff on novel glycosylation analysis technology development in the Journal of Chromatography A (see in References and Staff publications in the Menu).

28.08.2013: INDEVION Biotech signs contract with UD-Genomed Medical Genomic Technologies Ltd for the development of novel reporter cell line systems for therapeutic antibody production QC.

06.05.2013: INDEVION presents its epitope mapping applications at Roche GS Junior NGS User Meeting in Agárd, Hungary.

25.02.2013: INDEVION signs contract with Technology Park Debrecen to direct a cell engineering technology development project.

11-15.02.2013: INDEVION Biotech presents genome engineering advancements at Informa Cell Line Development and Engineering Conference, NH Danube City, Vienna.

01.05.2012: INDEVION Biotech Ltd obtains contractd with UD-Genomed Medical Genomic Technologies Ltd for genome engineering-based cell line development research projects.
01.08.2011: INDEVION Biotech Ltd contracted with UD-Genomed Medical Genomic Technologies Ltd for a therapeutic antibody production development project.
01.07.2011: INDEVION Biotech Ltd enters into contract with UD-Genomed Medical Genomic Technologies Ltd for cell line engineering projects.
01.01.2011: INDEVION Biotech Ltd signs contract with UD-Genomed Medical Genomic Technologies Ltd for epigenetics technology development projects.
01.06.2010: INDEVION Biotech Ltd obtains contract with Medical and Health Sciences Center, University of Debrecen for phage display technology projects.

PROPRIETARY TEHCHNOLOGY &
IP DEVELOPMENT:
CHIP technology for therapeutic antibody development
TRANSFECTION technology
BIONANOPARTICLE-based drug screening/recovery
GLYCOSYLATION QUALITY CONTROL KITS for therapeutic antibodies
GENOME/CELL LINE ENGINEERING technology

INDEVION Biotechnology R&D Ltd. specialises in development-to-production of recombinant proteins via protein engineering towards biopharmaceuticals, biodiagnostics, bioanalytics, etc.

Proprietary platform technology development
Contract R&D
Protein and genomics services
Recombinant protein products
Biotechnology Consultation services